Optimizing Linezolid Dosing by Renal Function: A Population Pharmacokinetic Study.
Objectives: Linezolid is administered at a fixed dose of 600 mg twice daily for the treatment of Gram‐positive infections. However, recent population pharmacokinetic studies reveal considerable interpatient variability, resulting in subtherapeutic or supratherapeutic drug exposures. This study aimed...
| Published in: | Journal of Clinical Pharmacy & Therapeutics Vol. 2026; pp. 1 - 10 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | equations & formulas research tables/charts Journal Article |
| Published: |
Wiley-Blackwell
3/24/2026
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=192477351&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 192477351 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02694727 EV4 jtl: Journal of Clinical Pharmacy & Therapeutics issn: 02694727 maglogo: Y pubinfo: dt: 3/24/2026 vid: 2026 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 192477351 192477351 192477351 10.1155/jcpt/6640426 192477351 ppf: 1 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Optimizing Linezolid Dosing by Renal Function: A Population Pharmacokinetic Study. aug: au: Ha, Khue N. Y. Tran, Ngan T. K. Nguyen, Cuc T. Nguyen, Thu T. A. Vu, Nhi T. L. Nguyen, Truc T. T. Vo, Cam T. N. Lu, Vy T. Do, Quan D. Duong, Diem N. Bui, Khanh H. T. Vu, Hoa D. Dang-Nguyen, Doan-Trang Bondareva, Irina B. affil: School of Pharmacy,, University of Medicine and Pharmacy at Ho Chi Minh City,, Ho Chi Minh, Vietnam, hcmut.edu.vn sug: subj: Gram-Positive Bacterial Infections Drug Therapy Cross Infection Drug Therapy Linezolid Pharmacokinetics Linezolid Administration and Dosage Linezolid Therapeutic Use Kidney Physiology Hospitalization Human Male Female Middle Age Aged Aged, 80 and Over Prospective Studies Vietnam Inpatients Administration, Intravenous Confidence Intervals Descriptive Statistics ROC Curve Drug Monitoring Middle Aged: 45-64 years Aged: 65+ years Aged, 80 & over Male Female ab: Objectives: Linezolid is administered at a fixed dose of 600 mg twice daily for the treatment of Gram‐positive infections. However, recent population pharmacokinetic studies reveal considerable interpatient variability, resulting in subtherapeutic or supratherapeutic drug exposures. This study aimed to describe the pharmacokinetics of linezolid in hospitalized infectious patients across varying degrees of renal function and propose optimized dosing strategies. Methods: Population pharmacokinetic modeling was performed using Monolix Version 2024R1. The model was evaluated using goodness‐of‐fit plots, bootstrap analysis, and prediction‐corrected visual predictive checks. Appropriate dosing regimens for different levels of renal function and minimum inhibitory concentrations were proposed by Monte Carlo simulations. Results: Fifty‐five adult patients with a total of 178 linezolid concentration measurements were included. A two‐compartment model with first‐order absorption and linear elimination best described the pharmacokinetic data. Volume of distribution and clearances were scaled using an allometric weight model. In addition, creatinine clearance (CLcr) significantly affected linezolid clearance. Simulation results suggested that patients with CLcr ≤ 30 mL/min may require reduced doses (600–900 mg daily), whereas those with CLcr ≥ 110 mL/min may benefit from increased doses (600 mg every 8 h). Conclusions: Individualization of linezolid dosing based on renal function is warranted. Therapeutic drug monitoring is recommended for patients with impaired or augmented renal clearance to optimize the therapeutic efficacy and minimize the risk of toxicity. pubtype: Academic Journal doctype: equations & formulas research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|